Selumetinib is currently FDA approved for children 2 years and older with symptomatic and inoperable plexiform neurofibromas.

Panelists discuss how MEK inhibitors, such as trametinib and selumetinib, are emerging as first-line treatments for symptomatic NF1-associated plexiform neurofibromas, especially in progressive or ...

Summary for Physicians Current Management Goals for NF1-PN The primary goals in managing neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) are to control tumor growth, manage ...

The Philippine Food and Drug Administration approves a game-changing prescription medicine, Selumetinib.

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

while Gomekli could knock on the door of $1 billion in sales as the first medicine approved for use in both adults and children with plexiform neurofibromas (PN) associated with NF1. Its only ...

A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

The realization began to sink in — he wasn’t the only one.

This content was created by our physicians and experts. Neurofibromatosis is a genetic disorder characterized by tumors known as neurofibromas, which grow in the nervous system and under the skin.

News, opinions and meeting coverage in surgery.